FDA Brief

Warning letters Drugs

FDA warning letter to

Root Bioscience Brands, LLC dba Naternal

High riskIssued Aug 30, 2024Posted Sep 10, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Naternal that its CBD oils, gummies, and pet hemp oil are unapproved drugs due to drug claims.

What happened

FDA reviewed www.naternal.com in August 2024 and found products represented to contain CBD, CBG, and CBN, with website claims that they treat conditions such as high blood pressure, Alzheimer's, PTSD, autism, cancer, glaucoma, and opioid addiction. FDA also found pet hemp oil claims and customer-review replies about seizures, arthritis, and diabetes in pets. FDA determined the human products are unapproved new drugs and the pet products are unapproved new animal drugs.

What FDA found

  1. The CBD oil and gummy products were marketed with claims to treat diseases and affect body functions, making them drugs, but they have no FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. FDA treats the products as new drugs because they are not generally recognized as safe and effective for the claimed uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. The pet hemp extract oils were marketed to treat seizures, arthritis, and diabetes in animals, but FDA says they are not approved or legally listed and are therefore unsafe under the animal drug law.

    FD&C Act sections 512(a), 501(a)(5), and 301(a), 21 U.S.C. 360b(a), 351(a)(5), and 331(a)
  4. Website customer reviews and company replies were used as evidence that the pet products were intended to treat animal diseases.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. The company marketed CBD products for opioid addiction treatment, an unproven use that FDA says could cause patients to delay or forgo approved treatment.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations, prevent recurrence, and provide related documentation. If corrective action cannot be completed in that time, the company must state why and give a completion date, sending the response to FDAADVISORY@fda.hhs.gov.

Who should pay attention

  • CBD and hemp product brands that make health claims online
  • retailers and marketplaces selling CBD/hemp supplements
  • pet supplement sellers and veterinarians advising pet owners

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk